Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.08
ENDP's Cash to Debt is ranked lower than
94% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. ENDP: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
ENDP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.44 Max: No Debt
Current: 0.08
Equity to Asset 0.35
ENDP's Equity to Asset is ranked lower than
85% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ENDP: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
ENDP' s Equity to Asset Range Over the Past 10 Years
Min: 0.08  Med: 0.56 Max: 0.77
Current: 0.35
0.08
0.77
F-Score: 3
Z-Score: 0.03
M-Score: -2.59
WACC vs ROIC
2.75%
-2.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -30.28
ENDP's Operating margin (%) is ranked lower than
85% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.87 vs. ENDP: -30.28 )
Ranked among companies with meaningful Operating margin (%) only.
ENDP' s Operating margin (%) Range Over the Past 10 Years
Min: -30.28  Med: 23.74 Max: 30.74
Current: -30.28
-30.28
30.74
Net-margin (%) -25.90
ENDP's Net-margin (%) is ranked lower than
84% of the 717 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. ENDP: -25.90 )
Ranked among companies with meaningful Net-margin (%) only.
ENDP' s Net-margin (%) Range Over the Past 10 Years
Min: -45.74  Med: 11.26 Max: 20.95
Current: -25.9
-45.74
20.95
ROE (%) -15.62
ENDP's ROE (%) is ranked lower than
79% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.03 vs. ENDP: -15.62 )
Ranked among companies with meaningful ROE (%) only.
ENDP' s ROE (%) Range Over the Past 10 Years
Min: -85.73  Med: 12.36 Max: 20.43
Current: -15.62
-85.73
20.43
ROA (%) -5.13
ENDP's ROA (%) is ranked lower than
75% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ENDP: -5.13 )
Ranked among companies with meaningful ROA (%) only.
ENDP' s ROA (%) Range Over the Past 10 Years
Min: -10.68  Med: 5.72 Max: 14.68
Current: -5.13
-10.68
14.68
ROC (Joel Greenblatt) (%) -128.11
ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.38 vs. ENDP: -128.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENDP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -128.11  Med: 141.4 Max: 718.27
Current: -128.11
-128.11
718.27
Revenue Growth (3Y)(%) -12.00
ENDP's Revenue Growth (3Y)(%) is ranked lower than
86% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. ENDP: -12.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENDP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12  Med: 20.3 Max: 26.9
Current: -12
-12
26.9
EBITDA Growth (3Y)(%) -1.50
ENDP's EBITDA Growth (3Y)(%) is ranked lower than
67% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. ENDP: -1.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ENDP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10  Med: 16.6 Max: 75.9
Current: -1.5
-10
75.9
EPS Growth (3Y)(%) -36.70
ENDP's EPS Growth (3Y)(%) is ranked lower than
90% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. ENDP: -36.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ENDP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.95 Max: 81.7
Current: -36.7
0
81.7
» ENDP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ENDP Guru Trades in Q3 2015

John Paulson 1,710,000 sh (New)
Steven Cohen 400 sh (New)
Kyle Bass 52,634 sh (+112.41%)
Diamond Hill Capital 20,050 sh (+56.03%)
RS Investment Management 419,901 sh (+11.89%)
Mario Gabelli 16,350 sh (+8.64%)
Steve Mandel 3,859,641 sh (+8.11%)
Wallace Weitz 972,478 sh (+1.18%)
John Griffin 4,200,000 sh (unchged)
Jim Simons Sold Out
Dodge & Cox Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 541,141 sh (-3.81%)
George Soros 2,016,984 sh (-12.30%)
Larry Robbins 6,944,273 sh (-21.42%)
Paul Tudor Jones 22,703 sh (-55.12%)
» More
Q4 2015

ENDP Guru Trades in Q4 2015

Louis Moore Bacon 20,751 sh (New)
Andreas Halvorsen 4,520,954 sh (New)
Steven Cohen 396,500 sh (+99025.00%)
John Paulson 3,302,200 sh (+93.11%)
RS Investment Management 543,593 sh (+29.46%)
George Soros 2,163,967 sh (+7.29%)
Larry Robbins Sold Out
Steve Mandel Sold Out
Kyle Bass Sold Out
Mario Gabelli 14,700 sh (-10.09%)
Wallace Weitz 684,923 sh (-29.57%)
Diamond Hill Capital 13,567 sh (-32.33%)
John Griffin 2,050,000 sh (-51.19%)
Pioneer Investments 229,122 sh (-57.66%)
Paul Tudor Jones 8,009 sh (-64.72%)
» More
Q1 2016

ENDP Guru Trades in Q1 2016

David Dreman 792 sh (New)
Jim Simons 569,260 sh (New)
Paul Tudor Jones 64,148 sh (+700.95%)
John Paulson 9,517,500 sh (+188.22%)
RS Investment Management 1,368,053 sh (+151.67%)
Wallace Weitz 968,093 sh (+41.34%)
George Soros 103,200 sh (unchged)
John Paulson 119,900 sh (unchged)
John Griffin Sold Out
Louis Moore Bacon Sold Out
Mario Gabelli Sold Out
George Soros Sold Out
Andreas Halvorsen 4,468,744 sh (-1.15%)
Diamond Hill Capital 12,443 sh (-8.28%)
Pioneer Investments 140,434 sh (-38.71%)
Steven Cohen 228,000 sh (-42.50%)
» More
Q2 2016

ENDP Guru Trades in Q2 2016

Joel Greenblatt 1,036,004 sh (New)
Arnold Schneider 445,225 sh (New)
David Dreman 10,670 sh (+1247.22%)
Steven Cohen 2,521,434 sh (+1005.89%)
RS Investment Management 1,374,185 sh (+0.45%)
John Paulson 119,900 sh (unchged)
Wallace Weitz Sold Out
Diamond Hill Capital Sold Out
Andreas Halvorsen Sold Out
John Paulson 8,956,300 sh (-5.90%)
Paul Tudor Jones 17,296 sh (-73.04%)
Pioneer Investments 28,618 sh (-79.62%)
Jim Simons 11,005 sh (-98.07%)
» More
» Details

Insider Trades

Latest Guru Trades with ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:OPK, NAS:NBIX, OTCPK:HYPMY, OTCPK:IPSEY, NYSE:TARO, OTCPK:ORINY, OTCPK:SFOSF, OTCPK:STDAF, NAS:AKRX, NAS:HZNP, NYSE:CTLT, OTCPK:INVVY, OTCPK:MDABY, NAS:MDCO, OTCPK:DNPUF, NAS:RDUS, NYSE:DPLO, NAS:IRWD, NYSE:RDY, NAS:IPXL » details
Traded in other countries:ENL.Canada, EO7.Germany,
Endo International PLC is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices.

Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. The Compnay's business segments are U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as its urology and men's health, endocrinology and orthopedic products. The marketed products that are included in this segment include Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including high barrier to entry products, first to file or first to market opportunities, that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The product offerings of this segment include products in the pain management, urology, CNS disorders, immunosuppression, oncology, women's health and cardiovascular disease markets. The International Pharmaceuticals segment includes a variety of specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Paladin, based in Canada, has a portfolio of products serving growing therapeutic areas, including ADHD, pain, women's health and oncology. Somar, based in Mexico, develops, manufactures and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives. Litha, based in South Africa, is a diversified healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs. The Company's competitors include Abbott Laboratories, Allergan plc, Purdue Pharma, L.P., Jazz Pharmaceuticals plc, Shire plc, Horizon Pharma plc, and Mallinckrodt plc, Teva Pharmaceutical Industries, Mylan, Inc., and Impax Laboratories, Inc. The Company has 352 U.S. issued patents, 190 U.S. patent applications pending, 856 foreign issued patents, and 510 foreign patent applications pending. It also has licenses for 81 U.S. issued patents, 56 U.S. patent applications pending, 334 foreign issued patents and 139 foreign patent applications pending. In the United States, the development, testing, manufacture, holding, packaging, labeling, distribution, marketing, and sales of its products and the ongoing product development activities are subject to and rigorous government regulation.

Guru Investment Theses on Endo International PLC

Weitz Funds Comments on Endo International - Jul 20, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Apr 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain patch).

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Jan 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities in 7 companies
Introduction Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities with 7 companies
Introduction Read more...
Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.
From Read more...
Wally Weitz Drops Falling Drug Stock Endo but Sees 'Upside Potential' Possibly short-term headwinds prompted 75 percent market sell-off this year
Wally Weitz, founder and chief investment officer of Weitz Investment Management, informed clients via a one-off note Thursday that his firm exited it entire position in pharmaceutical company Endo International, whose stock has dwindled to a quarter of its market value year to date. Read more...
Wallace Weitz Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain Read more...
Wallace Weitz Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.
From Read more...
John Paulson Keeps Gold, Buys Drug Manufacturers in Q3 Investor increases health care bet as M&A activity abounds in sector
John Paulson (Trades, Portfolio) made billions in the housing crash and employs an event-driven arbitrage investing strategy at his firm Paulson & Co., where he manages about $19.5 billion. Outsized bets tend to make the manager’s returns vary to extremes. For instance, in recent years his funds lost as much as 36% for 2014, after gaining as much as 46% in 2013. Read more...

Ratios

vs
industry
vs
history
Forward P/E 4.67
ENDP's Forward P/E is ranked higher than
95% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.89 vs. ENDP: 4.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.75
ENDP's P/B is ranked higher than
91% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.04 vs. ENDP: 0.75 )
Ranked among companies with meaningful P/B only.
ENDP' s P/B Range Over the Past 10 Years
Min: 0.53  Med: 2.67 Max: 17.5
Current: 0.75
0.53
17.5
P/S 1.20
ENDP's P/S is ranked higher than
78% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. ENDP: 1.20 )
Ranked among companies with meaningful P/S only.
ENDP' s P/S Range Over the Past 10 Years
Min: 0.81  Med: 2.56 Max: 6
Current: 1.2
0.81
6
PFCF 8.46
ENDP's PFCF is ranked higher than
90% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.70 vs. ENDP: 8.46 )
Ranked among companies with meaningful PFCF only.
ENDP' s PFCF Range Over the Past 10 Years
Min: 4.69  Med: 9.84 Max: 250.64
Current: 8.46
4.69
250.64
POCF 6.52
ENDP's POCF is ranked higher than
88% of the 248 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.32 vs. ENDP: 6.52 )
Ranked among companies with meaningful POCF only.
ENDP' s POCF Range Over the Past 10 Years
Min: 4.02  Med: 9.67 Max: 212.54
Current: 6.52
4.02
212.54
Current Ratio 0.90
ENDP's Current Ratio is ranked lower than
90% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ENDP: 0.90 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.9 Max: 3.55
Current: 0.9
0.9
3.55
Quick Ratio 0.69
ENDP's Quick Ratio is ranked lower than
89% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ENDP: 0.69 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.64 Max: 3.34
Current: 0.69
0.69
3.34
Days Inventory 102.51
ENDP's Days Inventory is ranked higher than
56% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. ENDP: 102.51 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 80.55  Med: 102.16 Max: 148.08
Current: 102.51
80.55
148.08
Days Sales Outstanding 86.23
ENDP's Days Sales Outstanding is ranked lower than
58% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.29 vs. ENDP: 86.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.33  Med: 108.55 Max: 171.52
Current: 86.23
71.33
171.52
Days Payable 45.17
ENDP's Days Payable is ranked lower than
72% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.16 vs. ENDP: 45.17 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 45.17  Med: 151.89 Max: 300.35
Current: 45.17
45.17
300.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.10
ENDP's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 424 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. ENDP: -26.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENDP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -0.6 Max: 4.7
Current: -26.1
-26.1
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.53
ENDP's Price/Projected FCF is ranked higher than
94% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. ENDP: 0.53 )
Ranked among companies with meaningful Price/Projected FCF only.
ENDP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.39  Med: 0.73 Max: 2.28
Current: 0.53
0.39
2.28
Price/Median PS Value 0.47
ENDP's Price/Median PS Value is ranked higher than
92% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. ENDP: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
ENDP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.35  Med: 1.27 Max: 3.25
Current: 0.47
0.35
3.25
Earnings Yield (Greenblatt) (%) -10.00
ENDP's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ENDP: -10.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENDP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -10  Med: 8.35 Max: 26.8
Current: -10
-10
26.8
Forward Rate of Return (Yacktman) (%) 30.52
ENDP's Forward Rate of Return (Yacktman) (%) is ranked higher than
90% of the 331 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.18 vs. ENDP: 30.52 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENDP' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.9  Med: 30.3 Max: 63.3
Current: 30.52
3.9
63.3

More Statistics

Revenue (TTM) (Mil) $3,704
EPS (TTM) $ -4.35
Beta0.31
Short Percentage of Float6.04%
52-Week Range $12.56 - 84.57
Shares Outstanding (Mil)222.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 3,934 4,134 4,124
EPS ($) 4.50 4.94 5.23
EPS w/o NRI ($) 4.50 4.94 5.23
EPS Growth Rate
(3Y to 5Y Estimate)
0.69%
Dividends Per Share ($)
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
US Market Indexes Reach New Highs Aug 09 2016 
Weitz Funds Comments on Endo International Jul 20 2016 
Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary Jul 20 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 
George Soros Sells Dow Chemical, Delta Air Lines Jun 06 2016 
Wally Weitz Sells Stake in Endo International, a Stock Down 75% May 26 2016 
The PBM Empire Strikes Back May 10 2016 
Wallace Weitz Comments on Endo International Apr 22 2016 

More From Other Websites
Five Small-Cap Stocks That Hedge Funds Were Dumping in Q2 Aug 24 2016
ETF’s with exposure to Endo International Plc : August 19, 2016 Aug 19 2016
Endo's President and CEO Adopts 10b5-1 Trading Plan Aug 18 2016
Endo's President and CEO Adopts 10b5-1 Trading Plan Aug 18 2016
Endo's President and CEO Adopts 10b5-1 Trading Plan Aug 18 2016
Endo International Plc :ENDP-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Aug 18 2016
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER Aug 16 2016
Salesforce.com Downgraded After Weak Sales-Channel Checks Aug 15 2016
Good, bad, ugly: XLY, SJM & ENDP Aug 15 2016
Is Valeant a Good Bet on a Price-to-Earnings Basis? Aug 15 2016
ENDO INTERNATIONAL PLC Financials Aug 13 2016
Endo withdraws filing seeking abuse deterrent labeling for pain drug Aug 12 2016
Endo (ENDP) Stock Climbs as Mizuho Upgrades to 'Buy' Aug 12 2016
Endo International: Baby Valeant Gets an Upgrade Aug 12 2016
What Are Valeant’s New Segments? Aug 12 2016
Stocks Slip On July Data; Acacia Sparks Fly On Q2 Win Aug 12 2016
Morning Movers: JC Penney Jumps on Earnings; Macy's Slips on Downgrade Aug 12 2016
Endo Pharma to withdraw application for new opioid painkiller formulation Aug 12 2016
Endo Withdraws Its SNDA For OPANA, Shares Rise Aug 12 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)